Hospital de Sagunto

The trials here

What the 9 trials at this site are about, from their registry records.

Conditions

• Asthma2 trials
• Crohn's disease2 trials
• IgA nephropathy2 trials
• Bladder cancer1 trial
• Kidney cancer1 trial
• Lupus (SLE)1 trial
• Metastatic breast cancer1 trial
• Prostate cancer1 trial
• Ulcerative colitis1 trial

Phase

• Phase 35 trials
• Phase 21 trial
• Phase 41 trial

Status

• Completed3 trials
• Recruiting3 trials
• Withdrawn3 trials

Lead sponsor

• Novartis Pharmaceuticals2 trials
• Takeda2 trials
• Galaxia Empírica1 trial
• Inmunotek S.L.1 trial
• Spanish Breast Cancer Research Group1 trial
• and 2 more

Running trials

• Recruiting

  Observational Study of the Effectiveness of Funded Drugs for Genitourinary Tumors.

  NCT06724159· Spanish Oncology Genito-Urinary Group· Source

  Contact: A responsible person Designated by the Sponsor

• Active, not recruiting

  Atrasentan in Patients With IgA Nephropathy

  NCT04573478· Phase 3· Novartis Pharmaceuticals· Source

• Recruiting

  A Prospective Registry Study in Patients With Unresectable Locally Advanced or Metastatic Breast Cancer (MBC)

  NCT02819882· Spanish Breast Cancer Research Group· Source

  Contact: MS Study Project Manager

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Bladder cancer1 recruiting
• IgA nephropathy1 recruiting
• Kidney cancer1 recruiting
• Metastatic breast cancer1 recruiting
• Prostate cancer1 recruiting

Closed trials

• Withdrawn

  Triple vs High Dose Inhaled CORticosteroids

  NCT05919394· Phase 4· Galaxia Empírica· Source

• Recruiting

  A Study of Vedolizumab in Children With Ulcerative Colitis (UC) or Crohn's Disease (CD)

  NCT05442567· Phase 3· Takeda· Source

• Terminated

  Study of Efficacy and Safety of LNP023 in Participants With Active Lupus Nephritis Class III-IV, +/- V

  NCT05268289· Phase 2· Novartis Pharmaceuticals· Source

• Recruiting

  A Study of Vedolizumab in Children and Teenagers With Moderate to Severe Crohn's Disease (CD)

  NCT04779320· Phase 3· Takeda· Source

• Recruiting

  Efficacy and Safety Evaluation for the Treatment of Allergy Against Mites

  NCT04435990· Phase 3· Inmunotek S.L.· Source

• Completed

  A Study of the Effect and Safety of Sparsentan in the Treatment of Patients With IgA Nephropathy

  NCT03762850· Phase 3· Travere Therapeutics, Inc.· Source